Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable.

Lok AS, Ward JW, Perrillo RP, McMahon BJ, Liang TJ.

Ann Intern Med. 2012 May 15;156(10):743-5. doi: 10.7326/0003-4819-156-10-201205150-00013. No abstract available.

2.

American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Perrillo RP, Gish R, Falck-Ytter YT.

Gastroenterology. 2015 Jan;148(1):221-244.e3. doi: 10.1053/j.gastro.2014.10.038. Epub 2014 Oct 31. Review. No abstract available.

PMID:
25447852
3.

American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT; American Gastroenterological Association Institute.

Gastroenterology. 2015 Jan;148(1):215-9; quiz e16-7. doi: 10.1053/j.gastro.2014.10.039. Epub 2014 Oct 31. Review. No abstract available. Erratum in: Gastroenterology. 2015 Feb;148(2):455. multiple investigator names added.

PMID:
25447850
4.

The difficulties of managing severe hepatitis B virus reactivation.

Roche B, Samuel D.

Liver Int. 2011 Jan;31 Suppl 1:104-10. doi: 10.1111/j.1478-3231.2010.02396.x. Review.

PMID:
21205146
5.

Hepatitis B: old virus, new problems?

Barbara JA.

Vox Sang. 1994;67 Suppl 3:239-42. Review. No abstract available.

PMID:
7975500
6.

Hepatitis B virus reactivation associated with anti-neoplastic therapy.

Yeo W, Chan HL.

J Gastroenterol Hepatol. 2013 Jan;28(1):31-7. doi: 10.1111/j.1440-1746.2012.07280.x. Review.

PMID:
23020594
7.

Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy.

Ohishi W, Chayama K.

Clin Exp Nephrol. 2011 Oct;15(5):634-40. doi: 10.1007/s10157-011-0464-7. Epub 2011 Jun 1. Review.

PMID:
21629993
8.

Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.

Kusumoto S, Tanaka Y, Ueda R, Mizokami M.

J Gastroenterol. 2011 Jan;46(1):9-16. doi: 10.1007/s00535-010-0331-4. Epub 2010 Oct 6. Review.

PMID:
20924616
9.

Serological and molecular testing in hepatitis B and the dialysis patient.

Fabrizi F, Lunghi G, Martin P, Poordad FF.

Int J Artif Organs. 2002 Feb;25(2):91-9. Review. No abstract available.

PMID:
11905519
10.

Hepatitis B virus infection--natural history and clinical consequences.

Ganem D, Prince AM.

N Engl J Med. 2004 Mar 11;350(11):1118-29. Review. No abstract available. Erratum in: N Engl J Med. 2004 Sep 16;351(12):351.

PMID:
15014185
11.

[Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].

Muñoz Bertrán E, Pérez Ceballos E, Gómez Espín R, Ortega González I.

Gastroenterol Hepatol. 2010 May;33(5):377-81. doi: 10.1016/j.gastrohep.2010.01.010. Epub 2010 Apr 2. Review. Spanish.

PMID:
20363054
12.

Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy.

Manzano-Alonso ML, Castellano-Tortajada G.

World J Gastroenterol. 2011 Mar 28;17(12):1531-7. doi: 10.3748/wjg.v17.i12. 1531. Review.

13.

[Diagnostic tests: Serological markers of hepatitis B virus].

Daikoku M.

Nihon Rinsho. 2005 Jul;63 Suppl 7:404-7. Review. Japanese. No abstract available.

PMID:
16111286
14.

Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management.

Lubel JS, Angus PW.

J Gastroenterol Hepatol. 2010 May;25(5):864-71. doi: 10.1111/j.1440-1746.2010.06243.x. Review.

PMID:
20546439
15.

Chronic hepatitis B infection.

Kuo A, Gish R.

Clin Liver Dis. 2012 May;16(2):347-69. doi: 10.1016/j.cld.2012.03.003. Review.

PMID:
22541703
16.

Immunosuppression and HBV reactivation.

Shouval D, Shibolet O.

Semin Liver Dis. 2013 May;33(2):167-77. doi: 10.1055/s-0033-1345722. Epub 2013 Jun 8. Review.

PMID:
23749673

Supplemental Content

Support Center